Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Évaluation de la sécurité et de l'efficacité en vie réelle des participants atteints d'amyotrophie spinale traités par Onasemnogène Abeparvovec-brve intrarachidien (OAV101B) (ITVISMA®) : Une étude pragmatique multicentrique américaine (STREAM)

28 octobre 2026 mis à jour par: Novartis Pharmaceuticals

Onasemnogène Abeparvovec : Évaluation de la sécurité et de l'efficacité en vie réelle des participants atteints d'amyotrophie spinale traités par Onasemnogène Abeparvovec-brve intrathécal (ITVISMA®) : Une étude pragmatique multicentrique américaine (STREAM)

The primary purpose is to address critical evidence in the treatment landscape for Spinal Muscular Atrophy (SMA), specifically focusing on the intrathecal formulation of onasemnogene abeparvovec-brve (ITVISMA®). U.S. Pragmatic Multicenter Study (STREAM).

Aperçu de l'étude

Statut

Recrutement

Description détaillée

STREAM is a prospective, multicentre cohort study that will follow U.S. participants with genetically confirmed SMA who receive a single, intrathecal dose of onasemnogene abeparvovec-brve. All eligible participants are enrolled prior to therapeutic injection. No randomisation, blinding, or placebo control is employed; instead, each participant acts as his or her own baseline comparator. This study will use an exploratory external cohort of patients matched by age, clinical characteristics, treatment history and availability of at least 1 year of pre-treatment medical history. This patient cohort will be based on a database of retrospectively collected electronic medical records data and will be used descriptively to contextualize study outcomes. Bias is minimised through pre-specified endpoints, uniform rater training on motor-function scales, and a detailed statistical analysis plan that stipulates handling of missing data and intercurrent events in advance.

Type d'étude

Interventionnel

Inscription (Estimé)

36

Phase

  • Phase 4

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

  • Nom: Novartis Pharmaceuticals

Lieux d'étude

    • Arkansas
      • Little Rock, Arkansas, États-Unis, 208833
        • Recrutement
        • Arkansas Children's Hospital
        • Chercheur principal:
          • Aravindhan Veerapandiyan
        • Contact:
          • Buffy Gofforth
          • Numéro de téléphone: (501) 364-1591
    • California
      • Stanford, California, États-Unis, 94305-5235
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Recrutement
        • Boston Childrens Hospital
        • Contact:
        • Chercheur principal:
          • Leslie Hayes
    • New York
      • New York, New York, États-Unis, 10032
        • Recrutement
        • Columbia University Medical Center
        • Chercheur principal:
          • Claudia Chiriboga
        • Contact:
    • Ohio
      • Columbus, Ohio, États-Unis, 43210
        • Recrutement
        • Ohio State University Medical Center
        • Chercheur principal:
          • Bakri Elsheikh
        • Contact:
    • Pennsylvania
      • Philadelphia, Pennsylvania, États-Unis, 209277
        • Recrutement
        • University of Pennsylvania
        • Chercheur principal:
          • Lauren Elman
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

2 ans à 100 ans (Enfant, Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Key Inclusion Criteria:

A participant will be enrolled in STREAM only if all the following conditions are met:

  • The participant has a genetically confirmed diagnosis of SMA (biallelic SMN1 deletion or mutation).

  • He or she is ≥ 2 years of age on the day of the intrathecal injection.

  • The treating Investigator intends to administer within the current episode of care, a single dose of ITVISMA® (1.2 × 10¹⁴ vg) in routine U.S. practice after written informed consent obtained.

  • One of the following functional categories applies at screening:

    1. independently ambulatory child/adolescent 2 - <18 years; or
    2. independently ambulatory adult (≥ 18 years).
    3. non-ambulatory (includes walkers with assistance) adult > 18 years with entry level RULM at baseline
  • At least 1 year of pre-treatment medical history, including motor-function documentation, can be retrieved from the site electronic record.

Key Exclusion Criteria:

A participant will be excluded if any of the following conditions apply:

  • Contraindication for lumbar puncture as determined by the investigator (e.g., spinal anatomy that precludes safe lumbar puncture)
  • An uncontrolled acute illness, active infection, febrile illness or acute medical condition, within 30 days prior to dosing
  • Inability to tolerate corticosteroids administered by mouth or gastrostomy tube
  • Current participation in another interventional clinical trial that would interfere with the objectives or endpoints of STREAM. Note: participation in observational cohort studies or non-interventional studies in which the participant does not receive treatment or undergo procedures which may compromise this study data integrity may be allowed following Sponsor approval
  • Planned relocation or any circumstance that is likely to prevent completion of the minimum 12-month follow-up.

Other protocol inclusion, exclusion criteria may apply.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Onasemnogene Abeparvovec-brve

Participants with spinal muscular atrophy, including:

  • independently ambulatory children/adolescents (≥ 2 years to < 18 years);
  • independently ambulatory adults (≥ 18 years);
  • Non-ambulatory adults (≥ 18 years)

administered once via lumbar puncture with systemic corticosteroid prophylaxis per label.

Autres noms:
  • (ITVISMA®)

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change from baseline in HFMSE for independently ambulatory participants
Délai: Baseline, 6, 12, 18 and 24 months

The HFMSE is a validated SMA specific assessment devised for use in children with SMA to give objective information on motor ability and clinical progression.

The HFMSE contains 33 items rated from 0 (unable to perform) to 2 (performs without modification/adaptation/compensation). Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Change from baseline in RULM for non-ambulatory (including walkers with assistance) participants
Délai: Baseline, 6, 12, 18 and 24 months

The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-ambulatory (including walkers with assistance) individuals with SMA. The scale consists of 19 scorable items: 18 items scored on 0 (unable) to 2 (full achievement) scale, and one item that is scored from 0 (unable) to 1 (able). Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: up to 5 years

Incidence of AEs and SAEs, including changes in laboratory tests and procedure-related events qualifying and reported as AEs.

up to 5 years
Modified SMA Functional Rating Scale (SMA-FRS) for independently ambulatory participants (≥ 18 years of age) and non-ambulatory particpants
Délai: Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5

Modified Spinal Muscular Atrophy Functional Rating Scale (SMAFRS): Ten items address questions related to eating, upper extremity dressing, lower extremity dressing, grooming, bathing, toileting, turning in bed and adjusting bed clothes, transfers, walking, and climbing stairs. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, 6, 12, 18 and 24 months and Years 3, 4, and 5
Assessment of Caregiver Experience with Neuromuscular Disease (ACEND) for independently ambulatory participants (<18 years of age)
Délai: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

The Assessment of Caregiver Experience with Neuromuscular Disease (ACEND): quantifies caregivers' perceptions of function and quality of life pertaining to time, finance and emotion. The ACEND was developed and validated to specifically assess caregiver impact experienced by raising children severely affected by neuromuscular diseases. While specifically developed for application to caregivers of patients undergoing orthopedic surgery, it has application to those with SMA. This outcome measure includes effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Subgroup outcomes: Hammersmith Functional Motor Scale Expanded (HFMSE)
Délai: Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The HFMSE is a validated SMA specific assessment to give objective information on motor ability and clinical progression. Total scores range from 0-66. Higher scores indicate higher levels of motor ability.

Baseline, 6, 12, 18 and 24 months
Subgroup outcomes: Revised Upper Limb Module (RULM)
Délai: Baseline, 6, 12, 18 and 24 months

Effectiveness assessment across predefined participant groups based on relevant clinical and demographic factors, as specified in the protocol. The RULM is a validated SMA specific assessment of motor performance in the upper limbs from childhood through adulthood in independent ambulatory and non-independent ambulatory individuals with SMA. Total scores range from 0-37 points. Higher scores reflect higher level of motor ability.

Baseline, 6, 12, 18 and 24 months
Frequency of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Délai: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Duration of hospitalizations emergency department visits, outpatient visits, respiratory interventions and nutritional support interventions
Délai: Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5

Assessment of SMA-related healthcare-resource utilisation.

Baseline, Months 6, 12, 18, 24, and Years 3, 4, and 5
Cobb angle
Délai: Baseline, up to 24 months

Assessment of scoliosis progression as a disease-progression marker.

Baseline, up to 24 months
Daily hours of respiratory support (none, non-invasive ventilation, invasive ventilation)
Délai: Baseline, up to 24 months

Assessment of respiratory function as a disease-progression marker.

Baseline, up to 24 months
Joint-range limitation measured by goniometer
Délai: Baseline, up to 24 months

Assessment of evolution of joint contractures as a disease-progression marker.

Baseline, up to 24 months
Nutritional-support category (oral, gastrostomy feeds, total parenteral nutrition)
Délai: Baseline, up to 24 months

Assessment of nutrition status as a disease-progression marker.

Baseline, up to 24 months
6-Minute Walk Test (6MWT) for ambulatory patients
Délai: Baseline, Months 6, 12, 18, and 24

To assess disease-progression markers. 6MWT: distance in metres; greater distance indicates better ambulatory capacity.

Baseline, Months 6, 12, 18, and 24

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

27 août 2026

Achèvement primaire (Estimé)

3 mai 2032

Achèvement de l'étude (Estimé)

30 juin 2032

Dates d'inscription aux études

Première soumission

26 février 2026

Première soumission répondant aux critères de contrôle qualité

26 février 2026

Première publication (Réel)

4 mars 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

29 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner